Date: 2012-01-09
Type of information: Collaboration agreement
Compound: drug/target profiling and drug discovery services
Company: NiKem Research (Italy) Dualsystems Biotech (Switzerland)
Therapeutic area:
Type agreement: collaboration
Action mechanism:
Disease:
Details: Dualsystems Biotech and NiKem Research have formed a strategic alliance to jointly offer their respective drug/target profiling and drug discovery services to their clients.
Dualsystems offers a proprietary suite of technologies for drug and target profiling from a client’s phenotypic assays. Based on its advanced platforms to discover protein interactions, mechanism of action and target network, information is generated at an early stage of hit-to-lead, lead optimisation or candidate selection. These skills are complemented by the synthetic and medicinal chemistry expertise, the ADMET & DMPK and early toxicology services that NiKem has been providing to its clients over the last 10 years. The combined skills that Dualsystems and NiKem can now offer via a single point of contact make for a highly efficient drug discovery engine. All generated intellectual property is assigned to the client.
Dualsystems’ and NiKem’s combined technologies will help clients speed up their drug development by providing real-time information about drug candidates, their targets, their mechanisms of action and allow for a seamless downstream development of the molecules of interest.
Financial terms: Financial details were not disclosed
Latest news:
